Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Embattled biotechnology firm Novavax (NASDAQ: NVAX ) — which previously incurred serious business viability risks — received much-needed positive news. On Friday after market close, the Canadian government announced that it will pay $349.6 million to settle a dispute surrounding its forfeiture of certain doses of Novavax's Covid-19 vaccine previously scheduled for delivery.

Why Is Novavax (NVAX) Up 30% Today?

Novavax shares moved higher after the vaccine maker announced that it would be paid $349.6 million from Canada for an unspecified quantity of forfeited COVID-19 vaccines previously set for delivery. Canada will pay the Maryland-based company in two equal installments in 2023, Novavax said in a Securities and Exchange Commission (SEC) filing.

Novavax to be paid $350M from Canada for unused COVID-19 vaccines; shares rise

Novavax's only commercial product line is COVID-19 vaccines. The company will receive payment from Canada for unused COVID-19 shots.

Why Shares of Novavax Are Up Monday

In February, the company said there was 'substantial doubt' about its ability to continue operating through this year.

Novavax Stock Surges 26%. It's Getting $350 Million for Canceled Covid Shots.

Canada's Covid shot settlement is a sign of hope for investors after Novavax raised doubts about its ability to stay in business earlier this year.

Novavax stock spikes 20% after company snags $350 million from Canada for unused Covid shots

Novavax Inc said on Friday Canada will pay $349.6 million to settle the forfeiting of certain doses of its COVID-19 vaccine previously scheduled for delivery.

Novavax to receive $350 mln from Canada for unused COVID shots

Novavax's (NVAX) protein-based COVID-19 vaccine, Nuvaxovid, gets full marketing authorization for COVID patients in Europe.

Novavax's (NVAX) COVID Jab Gets Full Approval in Europe

Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU Marketing Authorization includes use of Nuvaxovid™ as a primary series in individuals aged 12 and older and booster in adults Marketing Authorization provides regulatory foundation for future vaccine updates, including Fall vaccination campaign GAITHERSBURG, Md. , July 6, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, has been granted full Marketing Authorization (MA) by the European Commission in the European Union (EU) for Nuvaxovid™ (NVX-CoV2373).

Novavax's Nuvaxovid™ Receives Full Marketing Authorization in the EU for the Prevention of COVID

Moderna

Pfizer

All three companies are working on updated vaccines for COVID. A new variant, XBB.1.5, led to a spike in COVID cases in China earlier this year.

A Big Test Is Looming for Pfizer, Moderna, and Novavax

Nokia

Sirius XM Holdings Inc

Tencent Music Entertainment Group 

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 ‘Strong Buy' Stocks Under $10 Are Household Names and Could Explode Higher

C3.ai

Carvana

Lovesac Company

Mobileye Global Inc

While it seems like a million years ago now, who can ever forget the incredible rise of GameStop (and other highly shorted stocks) starting in January of 2021 and again later that year?

Why 5 of the Most Crowded Short Sale Stocks Could Be Ready to Explode Higher

Big Lots

Beyond Meat

Selling stocks short is a practice that's once again facing criticism, and a potential ban, following the collapse of multiple regional banks earlier in the year. Short selling is a risky practice where investors borrow shares, sell said shares (expecting their price to fall), then later buying these shares at a discount and pocket the difference.

Get Out Now! 3 Stocks to Dump Before the Short-Selling Ban.

Pharmaceutical stocks are trailing the market this year. So far in 2023, the Dow Jones U.S. Select Pharmaceuticals Index is down 5.4% while all three major indices are positive on the year.

3 Pharma Stocks That Have Big Investors Running for the Exit

VanEck Vectors Biotech ETF

First Trust Morningstar Dividend Leaders Index Fund

First Trust Nasdaq Pharmaceuticals ETF 

Amplify Treatments Testing & Advancements ETF

iShares Core High Dividend ETF

Invesco Nasdaq Biotechnology ETF

Horizon Kinetics Medical ETF

Invesco Dynamic Pharmaceuticals ETF

The FDA advised to Pfizer, Moderna and Novavax to manufacture single-strain jabs targeting the omicron subvariant XBB.1.5 should prove to be a victory for some biotech ETFs.

Biotech ETFs in Focus on Covid Vaccines' Fall Rollout

The FDA's strain selection puts Pfizer, Moderna and Novavax on track to deliver updated coronavirus shots in time for the fall.

Pfizer, Moderna and Novavax gear up for fall Covid vaccine rollout with an important head start

Novavax is preparing to launch an updated coronavirus vaccine this fall, along with bigger rivals Pfizer and Moderna. The company also is in the middle of a restructuring effort that involves a potential 50% reduction in expenses.

What Do Bears Know About Novavax That Bulls Don't?

BioNTech SE

The U.S. Food and Drug Administration (FDA) said on Friday it has advised manufacturers that are updating their COVID-19 vaccines to develop monovalent shots to target the XBB.1.5 subvariant.

US FDA advises COVID vaccine makers to develop shots aimed at XBB.1.5 variant

The FDA's decision is a win for vaccine makers Pfizer, Moderna and Novavax, which have all been developing versions of their Covid shots to target XBB.1.5.

FDA recommends that updated Covid shots target omicron subvariant XBB.1.5 this fall

An FDA panel unanimously recommends updating COVID vaccines to target one of the currently dominating XBB strains of the virus.

FDA Panel Endorses Updating COVID Jab to Target XBB Strain

Lumen Technologies

Not all stocks are worthy of investor capital. Today, we'll be looking at three poor-performing stocks to avoid.

Exit Strategy: Get Out of These 3 Poor-Performing Stocks Now

Novavax has developed a protein-based monovalent XBB.1.5 COVID vaccine candidate and is manufacturing at commercial scale with the intent to be in market during the fall vaccination campaign Novavax shared data demonstrating that its XBB.1.5 COVID vaccine candidate induces functional immune responses to XBB subvariants including XBB.1.5, XBB.1.16 and XBB.2.3 If authorized, Novavax's protein-based vaccine candidate would be the only non-mRNA XBB.1.5 vaccine available in the U.S. Novavax intends to supply vaccine globally, consistent with FDA, WHO and EMA recommendations GAITHERSBURG, Md. , June 15, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, participated in today's U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee's (VRBPAC) meeting, which resulted in a unanimous vote recommending updating the current COVID vaccine composition to a monovalent XBB-lineage.

Novavax Prepared to Deliver Protein-based Monovalent XBB COVID Vaccine Consistent with FDA VRBPAC Recommendation for the Fall

GAITHERSBURG, Md. , June 15, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Company has adjourned its 2023 Annual Meeting of Stockholders (the "Annual Meeting"), originally scheduled to be held on June 15, 2023, to July 11, 2023 at 8:30 a.m.

Novavax Announces Adjournment of 2023 Annual Meeting of Stockholders to July 11, 2023

Cash-strapped Covid vaccine Novavax still faces a nunber of challenges, chiefly competing with Pfizer and Moderna in the U.S. commercial market this fall.

Covid vaccine maker Novavax sees a pathway to survival – but it won't be easy

DraftKings

ImmunityBio

Luckin Coffee

Upstart Holdings

vTv Therapeutics

There are some similarities between gambling and buying high-risk, high-reward stocks. In both scenarios, you could make a great deal of money or you could lose all of it.

7 High-Risk, High-Reward Stocks to Buy in June

Novavax's hopes in the coronavirus vaccine market have largely faded. The company has little going on elsewhere.

News for Novavax Stock (NVAX)